

Product Data Sheet

Product Name: CCF642
Cat. No.: GC32893

Chemical Properties

Cas. No. 346640-08-2

SMILES O=C1N(C2=CC=C(OC)C=C2)C(S/C1=C/C3=CC=C([N+](O-)=O)S3)=S


Formula $C_{15}H_{10}N_2O_4S_3$ M.Wt 378.45

Solubility DMSO : ≥ 30 mg/mL (79.27 mM) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

CCF642 is a novel PDI-inhibiting compound with antimyeloma activity. The IC₅₀ is 2.9 $\mu\text{mol/L}$. In vitro: CCF642 inhibits PDI reductase activity about 100-fold more potently than the structurally distinct established inhibitors PACMA 31 and LOC14. CCF642 causes acute ER stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. In vivo: CCF642 displayed potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolonged the lifespan of C57BL/KaLwRij mice engrafted with 5TGM1-luc myeloma, an effect comparable to the first-line multiple myeloma therapeutic bortezomib. CCF642 can be given intravenously without injection.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

reactions in mice with 10 mg/kg.

[1]. Vatolin S et al. Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. Cancer Res. 2016 Jun 1;76(11):3340-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA